-+ 0.00%
-+ 0.00%
-+ 0.00%

Vanda presents new GEMINI-1 data on imsidolimab in generalized pustular psoriasis at EADV 2026

PUBT·10/02/2026 13:07:08
Listen to the news
Vanda presents new GEMINI-1 data on imsidolimab in generalized pustular psoriasis at EADV 2026
  • Vanda Pharmaceuticals flagged new clinical findings on imsidolimab in generalized pustular psoriasis for presentation at the 2026 EADV meeting.
  • Results will be presented in the future, during the Vienna conference running September 30 through October 3, 2026.
  • Data indicate treatment was associated with rapid improvement in inflammation-related blood markers in patients with the rare skin disease.
  • Separate analyses focus on immunogenicity and on improvements in pustulation severity from the GEMINI-1 study.
  • Imsidolimab is an IL-36 receptor antibody for an orphan indication, with expected regulatory and patent exclusivity into the late 2030s.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610020906PR_NEWS_USPR_____PH62594) on October 02, 2026, and is solely responsible for the information contained therein.